CIK 0000894158
- Non-accelerated filer
- Smaller reporting company
Theriva Biologics, Inc.
Sign in to watch- Ticker
- TOVX
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- Operating
- EIN
- 133808303
- Phone
- +1 734-332-7800
- Business address
- 9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE, MD, 20850
- Former names
- Synthetic Biologics, Inc., ADEONA PHARMACEUTICALS, INC., PIPEX PHARMACEUTICALS, INC., SHEFFIELD PHARMACEUTICALS INC, SHEFFIELD MEDICAL TECHNOLOGIES INC
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy CEO bought 7,100,679 shares at an average $7.22 ($103,281)
- 4 Open-market buy CEO bought 7,094,379 shares at an average $7.13 ($57,025)
- 4 Open-market buy CEO bought 7,116,079 shares at an average $6.75 ($200,351)
- 4 Open-market buy CEO bought 7,111,379 shares at an average $5.25 ($131,171)
- 4/A Open-market buy CEO bought 7,167,379 shares at an average $4.84 ($391,962)
- 4 Open-market buy CEO bought 7,167,379 shares at an average $0.72 ($5,139,836)
- 4 Open-market buy President bought 10,000 shares at $4.64 ($46,400)
- 4 Open-market buy Chief Executive Officer bought 26,500 shares at an average $5.30 ($140,350)
- 4 Open-market buy Chief Executive Officer bought 227,000 shares at an average $1.96 ($445,580)
- 4 Grant or award Chief Executive Officer acquired 100,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Executive Officer acquired 95,238 shares (grant or award)
Page 7 of 8 · 156 filings